Sms Pharmaceuticals Ltd Stock Price Today (NSE: SMSPHARMA)
Fundamental Score
Sms Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sms Pharmaceuticals Ltd share price today is ₹375.95, down 0.12% on NSE/BSE as of 17 June 2026. Sms Pharmaceuticals Ltd (SMSPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.94K (Cr). The 52-week high for SMSPHARMA share price is ₹447.80 and the 52-week low is ₹207.70. At a P/E ratio of 36.26x, SMSPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.00% and a debt-to-equity ratio of 0.43.
Sms Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Sms Pharmaceuticals Ltd share price chart: -5.58% return over the past month. 52-week high ₹447.80, 52-week low ₹207.70.
Sms Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹359.00 | ₹365.90 | ₹354.10 | ₹363.95 | 1.24L (Cr) | |
| ₹369.25 | ₹371.00 | ₹357.50 | ₹359.50 | 2.67L (Cr) | |
| ₹379.95 | ₹381.40 | ₹367.10 | ₹369.25 | 1.60L (Cr) | |
| ₹378.45 | ₹380.75 | ₹374.20 | ₹377.35 | 2.02L (Cr) | |
| ₹373.20 | ₹380.90 | ₹370.00 | ₹376.25 | 3.84L (Cr) | |
| ₹385.00 | ₹389.40 | ₹361.70 | ₹369.15 | 8.91L (Cr) | |
| ₹432.65 | ₹438.45 | ₹374.00 | ₹381.45 | 21.34L (Cr) | |
| ₹428.50 | ₹432.80 | ₹422.10 | ₹425.85 | 2.51L (Cr) | |
| ₹408.00 | ₹426.00 | ₹406.75 | ₹424.30 | 2.81L (Cr) | |
| ₹393.70 | ₹418.05 | ₹393.70 | ₹410.25 | 1.58L (Cr) |
Sms Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹369.25 | ₹371.00 | ₹354.10 | ₹363.95 | -1.44% | |
| ₹406.10 | ₹438.45 | ₹361.70 | ₹369.25 | -9.07% | |
| ₹393.80 | ₹447.80 | ₹370.25 | ₹403.70 | +2.51% | |
| ₹372.00 | ₹433.90 | ₹356.20 | ₹374.85 | +0.77% | |
| ₹314.95 | ₹403.00 | ₹307.80 | ₹385.20 | +22.31% | |
| ₹309.40 | ₹360.00 | ₹293.15 | ₹316.60 | +2.33% | |
| ₹323.55 | ₹334.00 | ₹302.05 | ₹310.40 | -4.06% | |
| ₹283.95 | ₹335.00 | ₹270.10 | ₹319.20 | +12.41% | |
| ₹246.15 | ₹304.98 | ₹245.21 | ₹285.69 | +16.06% | |
| ₹237.80 | ₹312.40 | ₹231.00 | ₹245.66 | +3.31% | |
| ₹234.30 | ₹256.00 | ₹207.99 | ₹236.85 | +1.09% | |
| ₹251.60 | ₹258.70 | ₹225.15 | ₹234.30 | -6.88% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Small-cap API play faces valuation headwinds despite decent growth, liquidity a concern.
WHAT'S HAPPENING NOW (last 2-4 weeks)
SMS Pharmaceuticals reported Q3FY26 results with a net profit of Cr, a 28.67% YoY increase but a 7.27% QoQ decrease. Revenue stood at , up 21.40% YoY but down 13.19% QoQ. The company also received an income tax demand notice of Crores for the assessment year 2018-19. Trading window was closed from April 1, 2026, until 48 hours after the declaration of Q4 and FY26 financial results.
CORE STORY (THE REAL GAME)
SMS Pharma is an API manufacturer riding the wave of increased pharma exports and backward integration trends in the Indian pharma industry. The key is whether they can scale up the value chain into peptides and specialty CRO services.
- Q3FY26 results show YoY growth but QoQ decline.
- Income tax demand notice creates uncertainty.
- Trading window closure ahead of Q4 results.
- Significant API order wins.
- Successful integration of SMS Peptides.
- Reduction in promoter pledging.
- Small-cap: liquidity risk.
- High promoter pledging: 34.65%.
- QoQ revenue decline: 13.19%.
Promoter increased stake by 1.8%, FII increased stake by 0.25%, DII decreased stake by 0.15%.
Indian pharma sector projected to reach $130 billion by 2030, driven by global demand and innovation.
No: Free Cash Flow 5Y is ₹-94.11 Cr.
3-6 month thesis hinges on API demand and successful backward integration. Watch for Q4 results and any news on promoter pledging.
Primary Thesis Risk
Inability to maintain growth momentum and high valuation multiple.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sms Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sms Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SMSPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (17.68%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (76.30%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (23.22%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.70% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (15.88% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (6.25x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.06%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-94.11 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.16%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (34.65%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Sms Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sms Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sms Pharmaceuticals LtdSms Pharmaceuti...Selected✓ SMSPHARMA • 532815 | 37.3/100 | ₹375.95₹376 | ₹2942.52₹2942.52 | 36.26Average 36.3 Average | 11.00%Average 11.00% Average | 12.19%Average 12.19% Average | 0.43Excellent 0.4 Excellent | 15.88%Excellent 15.88% Excellent | 13.70%Good 13.70% Good | 0.13% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Sms Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for SMSPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹8.16 | ₹310.40 | 38x |
| FY 2024 | ₹5.89 | ₹238.85 | 40.6x |
| FY 2022 | ₹7.35 | ₹82.80 | 11.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Sms Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by SMSPHARMA — dividend yield 0.13%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹3.39 Cr |
| FY 2024 | ₹2.54 Cr |
| FY 2023 | ₹2.54 Cr |
| FY 2022 | ₹2.54 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Sms Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for SMSPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
23.22%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
76.30%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.70%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
15.88%
Compounded annual net profit growth over 5 years
Sms Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SMSPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sms Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Sms Pharmaceuticals Ltd (SMSPHARMA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Sms Pharmaceuticals Ltd
About SMSPHARMA (Sms Pharmaceuticals Ltd)
SMS Pharmaceuticals Ltd is a dynamic pharmaceutical company deeply rooted in the development, manufacture, and global distribution of critical active pharmaceutical ingredients (AP...Is) and advanced intermediates. Specializing in a diverse therapeutic spectrum, SMS Pharma addresses pressing health needs worldwide with products spanning anti-retrovirals vital for managing HIV, potent anti-inflammatory agents, and innovative antiviral solutions. Beyond these, their portfolio encompasses essential medicines for managing diabetes, fungal infections, epilepsy, migraines, and cardiovascular ailments. SMS Pharma is dedicated to producing high-quality, affordable solutions that improve patient outcomes and accessibility to crucial medications. Focusing on innovation and comprehensive pharmaceutical solutions, SMS Pharma also plays a key role in contract research, with particular expertise in peptide chemistry. This commitment to research and development underscores their dedication to expanding scientific understanding and creating new therapeutic avenues. By engaging in cutting-edge research, SMS Pharma solidifies its position as a forward-thinking player in the pharmaceutical landscape. Their dedication ensures a continuous pipeline of novel drug candidates and process improvements, benefiting both the company and the global healthcare community. SMS Pharma extends its reach far beyond its domestic borders, actively exporting its products to a broad network of approximately 75 countries. This international presence demonstrates not only the quality and reliability of their products but also their commitment to addressing global healthcare challenges. SMS Pharma's widespread distribution network facilitates access to vital medications for patients across diverse regions, affirming its role as a trusted and dependable supplier within the global pharmaceutical market. SMS Pharmaceuticals Ltd strives to reach more countries with innovative pharmaceutical manufacturing and development.
Company Details
Key Leadership
Corporate Events
SMSPHARMA Share Price: Frequently Asked Questions
What is the current share price of Sms Pharmaceuticals Ltd?
Sms Pharmaceuticals Ltd (SMSPHARMA) trades at ₹375.95 on NSE and BSE. Market cap ₹2.94K (Cr). Educational data only.
What is the P/E ratio of Sms Pharmaceuticals Ltd?
Sms Pharmaceuticals Ltd has a P/E of 36.26x vs industry average 31.77x.
What is the Bull Run score for Sms Pharmaceuticals Ltd?
Sms Pharmaceuticals Ltd has a Bull Run score of 37.3/100 based on 25+ financial parameters.
Does Sms Pharmaceuticals Ltd pay dividends?
Sms Pharmaceuticals Ltd has a dividend yield of 0.13%. Past dividends don't guarantee future payments.
What is the ROE of Sms Pharmaceuticals Ltd?
Sms Pharmaceuticals Ltd has ROE of 11.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sms Pharmaceuticals Ltd?
Sms Pharmaceuticals Ltd has debt-to-equity of 0.43.
Is Sms Pharmaceuticals Ltd a good investment?
Bull Run gives Sms Pharmaceuticals Ltd a score of 37.3/100. This is not investment advice — consult a SEBI-registered advisor.